A pharmaceutical company was preparing for a new indication in abdominal cancer. While patients in this disease state needed more effective treatment options, particularly once the disease had metastasized, oncologists had decades of experience with an effective agent for 1L treatment. Moreover, in the past few years an effective regimen had in the past few years become standard of care for many patients with a specific mutational status.

Given the increase in complexity in treatment this cancer—testing many biomarkers, interpreting these results, and planning out sequential lines of treatment—how would oncologists react to a new treatment in this space?

In-depth interviews revealed oncologists’ enthusiasm given positive efficacy markers, alongside some trepidation about access and coverage of these new agents. The insights highlighted the trade-offs and nuanced benefit/risk assessments oncologists were mentally making when assessing new treatment options, revealing the barriers the client could anticipate.